Table 1.
Baseline and end-point demographic and fasting biochemical data of placebo and stevioside group.
| Placebo | Stevisoide | |||
|---|---|---|---|---|
| Baseline | End-point | Baseline | End-point | |
| n, men/women | 19/27 | 18/26 | 34/26 | 32/24 |
| BMI (kg m−2) | 23.6 ± 2.8 | 23.4 ± 2.6 | 23.2 ± 2.5 | 23.3 ± 2.4 |
| Systolic BP (mmHg) | 166.0 ± 9.4 | 164.8 ± 8.7 | 166.5 ± 7.4 | 152.6 ± 6.8* |
| Diastolic BP (mmHg) | 104.7 ± 5.2 | 103.8 ± 5.4 | 102.1 ± 4.0 | 90.3 ± 3.6* |
| Heart rate (beats min−1) | 68.2 ± 7.8 | 69.4 ± 8.1 | 66.4 ± 7.2 | 67.4 ± 6.8 |
| Serum values | ||||
| Creatinine (µmol l−1) | 106.1 ± 26.5 | 97.2 ± 17.7 | 114.9 ± 26.5 | 106.1 ± 17.7 |
| CPK (U l−1) | 50 ± 18 | 49 ± 20 | 52 ± 17 | 49 ± 19 |
| AST (U l−1) | 16 ± 4 | 18 ± 7 | 15 ± 5 | 18 ± 9 |
| ALT (U l−1) | 20 ± 5 | 19 ± 6 | 21 ± 5 | 17 ± 6 |
| Na (mmol l−1) | 142.8 ± 6.0 | 140.8 ± 3.2 | 141.5 ± 5.1 | 140.2 ± 4.3 |
| K (mmol l−1) | 4.2 ± 0.4 | 4.5 ± 0.4 | 4.4 ± 0.4 | 4.4 ± 0.5 |
| Cl (mmol l−1) | 100.4 ± 14.8 | 100.9 ± 15.0 | 99.8 ± 3.5 | 98.3 ± 2.0 |
| Plasma values | ||||
| Glucose (mmol l−1) | 5.6 ± 0.8 | 5.4 ± 0.5 | 5.5 ± 0.7 | 5.3 ± 0.7 |
| Total cholesterol (mmol l−1) | 4.7 ± 1.0 | 5.1 ± 0.9 | 5.2 ± 1.0 | 5.1 ± 1.2 |
| HDL-C (mmol l−1) | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 |
| Triglycerides (mmol l−1) | 1.7 ± 0.9 | 1.7 ± 0.6 | 1.7 ± 0.6 | 1.7 ± 0.6 |
BMI indicates body mass index; CPK, creatinine phosphokinase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Na, sodium; K, potasium; and Cl, chloride. No significant difference was noted between placebo and stevioside groups at baseline. Values are mean ± s.d.. End-point vs baseline in each group.
*
P < 0.05.